Global Medical REIT Inc XRN Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$28.70 down $1.01, 3.40% at close Nov 6
Last close · Previous close $29.71
- Market cap
- $379.84MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- 8.01%Last 12 months
Price chart
$28.70down $1.01, 3.40%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$29.71Nov 5
- Volume170.28KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume217.08KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $28.09 to $38.65; now $28.70
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
XRN trailed the S&P 500 in all 7 periods.
| Period | XRN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XRN: down 15.8% S&P 500: down 5.6% | XRN trailed the S&P 500 by 10.2 percentage points Trailed |
| 3M | XRN: down 17.9% S&P 500: down 4.1% | XRN trailed the S&P 500 by 13.8 percentage points Trailed |
| YTD | XRN: down 11.1% S&P 500: up 8.7% | XRN trailed the S&P 500 by 19.8 percentage points Trailed |
| 1Y | XRN: down 5.3% S&P 500: up 10.9% | XRN trailed the S&P 500 by 16.2 percentage points Trailed |
| Long term | ||
| 3Y | XRN: down 19.8% S&P 500: up 75.0% −7.1% vs +20.5% a year | XRN trailed the S&P 500 by 94.8 percentage points Trailed |
| 5Y | XRN: down 49.2% S&P 500: up 67.8% −12.7% vs +10.9% a year | XRN trailed the S&P 500 by 117.0 percentage points Trailed |
| 10Y | XRN: up 53.4% S&P 500: up 313.1% +4.4% vs +15.2% a year | XRN trailed the S&P 500 by 259.7 percentage points Trailed |
$10,000 invested in XRN 10 years ago (Nov 4, 2016) would be worth about $15,335 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
XRN trailed the S&P 500 in all 7 periods.
| Period | XRN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XRN: down 16.3% S&P 500: down 5.6% | XRN trailed the S&P 500 by 10.7 percentage points Trailed |
| 3M | XRN: down 19.1% S&P 500: down 4.3% | XRN trailed the S&P 500 by 14.8 percentage points Trailed |
| YTD | XRN: down 14.9% S&P 500: up 7.8% | XRN trailed the S&P 500 by 22.7 percentage points Trailed |
| 1Y | XRN: down 11.3% S&P 500: up 9.7% | XRN trailed the S&P 500 by 21.0 percentage points Trailed |
| Long term | ||
| 3Y | XRN: down 37.6% S&P 500: up 68.8% −14.6% vs +19.1% a year | XRN trailed the S&P 500 by 106.4 percentage points Trailed |
| 5Y | XRN: down 66.3% S&P 500: up 56.9% −19.6% vs +9.4% a year | XRN trailed the S&P 500 by 123.2 percentage points Trailed |
| 10Y | XRN: down 31.0% S&P 500: up 252.6% −3.6% vs +13.4% a year | XRN trailed the S&P 500 by 283.6 percentage points Trailed |
$10,000 invested in XRN 10 years ago (Nov 4, 2016) would be worth about $6,899 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$91.95
Closing high on . Now 68.8% below that record.
Split-adjusted daily closes since Jun 29, 2016.
Stock splits
1
1-for-5 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
See the note under the price. Over the past five years XRN’s P/E ranged from 7.7× to 747.0×, with a median of 51.6×. How to read P/E
Other valuation measures
- 2.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - 7.4×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - 9.43%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.00BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own XRN DCF in Excel. Value Global Medical REIT with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $153.43Mup 8.0%
- Net income
- $57.95Mup 463.1%
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $34.26M | $3.25M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $35.16M | $2.83M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $34.62M | $3.56M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $37.97M | $655.00K | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $37.23M | −$4.55M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $38.39M | −$5.50M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $38.06M | $1.72M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $39.75M | $66.27M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $115.94M | $17.62M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $137.28M | $19.14M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $141.05M | $20.61M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $138.78M | $6.63M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $148.21M | −$5.84M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating 23.9%
- Net 37.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $35.82MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$75.11MLast 12 months
- Capital spending$39.28MLast 12 months
- 23.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $6.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$43.61MLast 12 months
- Total returned$49.61MLast 12 months
138% of free cash flow
Balance sheet
- Not reportedAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$633.12MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.96As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 10.8%Last 12 months
Over the last 12 months, Global Medical REIT’s net income was 10.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 4.5%Last 12 months
Over the last 12 months, Global Medical REIT’s net income was 4.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $2.00 |
| 2017 | $4.00 |
| 2018 | $4.00 |
| 2019 | $4.00 |
| 2020 | $4.00 |
| 2021 | $4.10 |
| 2022 | $4.20 |
| 2023 | $4.20 |
| 2024 | $4.20 |
| 2025 | $3.30 |
| 2026 (to date) | $1.55 |
Dividend details
- $2.30Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 8.01%; 5-yr low 1.70%, 5-yr high 15.99%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 8.50%.
- $0.16Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly9 payments in the last 12 months
- down 3.8% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- Payout ratioPausedLast 12 months
See the note under the price.
About Global Medical REIT Inc
Global Medical REIT is a net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.
- Sector
- Real Estate
- Industry
- REIT - Healthcare Facilities
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
XRN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
XRN stock FAQ
What is XRN stock’s price today?
Global Medical REIT (XRN) traded at $28.70 at the close on , down $1.01 (3.40%) from the previous close of $29.71. Over the past 52 weeks it has traded between $28.09 and $38.65.
If you invested $1,000 in XRN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in XRN on would be worth about $1,534 at the close on , a total return of +53.4%. The same $1,000 would be worth $508 if invested five years ago and $947 if invested one year ago. Past performance doesn’t predict future returns.
What is Global Medical REIT’s market cap?
Global Medical REIT’s market capitalization is about $379.8 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $28.70 (how market cap works).
How much revenue does Global Medical REIT make?
Global Medical REIT reported $153.4 million of revenue over the four quarters to , up 8.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $39.7 million, up 4.7% from a year earlier.
Is Global Medical REIT profitable?
Yes. Global Medical REIT earned $57.9 million of net income over the four quarters to , a net margin of 37.8%, and its operating margin was 23.9% (what margins tell you).
Does XRN pay a dividend?
Yes. Global Medical REIT pays a quarterly dividend. The most recent was $0.16 per share, with an ex-dividend date of . Over the last twelve months it paid $2.30 per share, a 8.01% yield at the close (how dividend yield works).
Based on the last 12 months’ payments ($2.30 per share), and if the next 12 months match the last 12, 100 shares would receive about $230 over 12 months, and $1,000 over 12 months would take about 435 shares, roughly $12,485 at the close. Dividends can change.
What is XRN’s 52-week high and low?
Over the past 52 weeks XRN has traded as low as $28.09 and as high as $38.65. At $28.70 at the close on , it is 25.7% below that high and 2.2% above the low.
What is XRN’s all-time high?
XRN’s highest closing price was $91.95 on , adjusted for stock splits. At $28.70 at the close on , it is 68.8% below that record.
Has XRN stock ever split?
Yes, once: 1-for-5 on .
How has XRN stock performed?
Including dividends and measured to the close on , XRN has returned −11.1% so far this year and −5.3% over the past year, and −49.2% over five years (−12.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Global Medical REIT in?
Global Medical REIT is in the Real Estate sector and the REIT - Healthcare Facilities industry, and is headquartered in Maryland, USA.
What exchange does XRN trade on?
Global Medical REIT trades on the NYSE under the ticker symbol XRN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.